Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAURUS MRD study in transplant-eligible newly diagnosed multiple myeloma
2023-505221-14-00Phase 2Authorised
- Sponsor
- European Myeloma Network
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, bortezomib, lenalidomide, dexamethasone, teclistamab and 3 more in multiple myeloma (MM), sponsored by European Myeloma Network. Planned start Dec 2023; status: authorised.
02
Drugs
daratumumabbortezomiblenalidomidedexamethasoneteclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-505221-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505221-14-00.